Optimizing the management of chronic obstructive pulmonary disease-reducing the risk of adverse cardiopulmonary event

doi:10.19983/j.issn.2096-8493.20230103

Abstract

CLC Number:

R563
R54

Chen Haijie, Chen Yahong. Optimizing the management of chronic obstructive pulmonary disease-reducing the risk of adverse cardiopulmonary event[J]. Journal of Tuberculosis and Lung Disease , 2023, 4(5): 337-341. doi: 10.19983/j.issn.2096-8493.20230103

References 48

[1]	Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med, 2018, 6(6):421-430. doi:10.1016/S2213-2600(18)30103-6. pmid: 29650407
[2]	Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis, 2018, 27(13):1353-1364. doi:10.2147/COPD.S161555.
[3]	Mannino DM, Higuchi K, Yu TC, et al. Economic Burden of COPD in the Presence of Comorbidities. Chest, 2015, 148(1):138-150. doi:10.1378/chest.14-2434. pmid: 25675282
[4]	André S, Conde B, Fragoso E, et al. COPD and Cardiovascular Disease. Pulmonology, 2019, 25(3):168-176. doi:10.1016/j.pulmoe.2018.09.006. pmid: 30527374
[5]	Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med, 2015, 3(8):631-639. doi:10.1016/S2213-2600(15)00241-6. pmid: 26208998
[6]	Ställberg B, Janson C, Larsson K, et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med, 2018, 28(1):33. doi:10.1038/s41533-018-0101-y.
[7]	Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest, 2005, 128(4):2640-2646. doi:10.1378/chest.128.4.2640. pmid: 16236937
[8]	Dalal AA, Shah M, Lunacsek O, et al. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med, 2011, 105(10):1516-1522. doi:10.1016/j.rmed.2011.04.005. pmid: 21684731
[9]	Natali D, Cloatre G, Hovette P, et al. Screening for comorbidities in COPD. Breathe (Sheff), 2020, 16(1):190315. doi:10.1183/20734735.0315-2019.
[10]	Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis, 2018, 12:1753465817750524. doi:10.1177/1753465817750524.
[11]	Brassington K, Selemidis S, Bozinovski S, et al. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease. Clin Sci (Lond), 2019, 133(7):885-904. doi:10.1042/CS20180316. pmid: 30979844
[12]	Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 2004, 59(7):574-580. doi:10.1136/thx.2003.019588. pmid: 15223864
[13]	Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J, 2009, 33(5):1165-1185. doi:10.1183/09031936.00128008. pmid: 19407051
[14]	Calverley PM, Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD, 2006, 3(4):233-242. doi:10.1080/15412550600977544. pmid: 17361504
[15]	Tousoulis D, Papageorgiou N, Androulakis E, et al. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev, 2011, 25(6):239-245. doi:10.1016/j.blre.2011.05.001. pmid: 21652129
[16]	Langer D, Ciavaglia CE, Neder JA, et al. Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Rev Respir Med, 2014, 8(6):731-749. doi:10.1586/17476348.2014.949676.
[17]	Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med, 2010, 362(3):217-227. doi:10.1056/NEJMoa0808836.
[18]	Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2005, 171(6):591-597. doi:10.1164/rccm.200407-867OC.
[19]	Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relation. Circ Res, 1989, 64(5):827-852. doi:10.1161/01.res.64.5.827. pmid: 2523260
[20]	Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med, 2015, 109(7):785-802. doi:10.1016/j.rmed.2015.03.010. pmid: 25892293
[21]	Ball MK, Waypa GB, Mungai PT, et al. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α. Am J Respir Crit Care Med, 2014, 189(3):314-324. doi:10.1164/rccm.201302-0302OC.
[22]	Tuder RM, Yun JH, Bhunia A, et al. Hypoxia and chronic lung disease. J Mol Med (Berl), 2007, 85(12):1317-1324. doi:10.1007/s00109-007-0280-4.
[23]	Goudis CA, Konstantinidis AK, Ntalas IV, et al. Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol, 2015, 199:264-273. doi:10.1016/j.ijcard.2015.06.096. pmid: 26218181
[24]	Laratta CR, van Eeden S. Acute exacerbation of chronic obstructive pulmonary disease: cardiovascular links. Biomed Res Int, 2014, 2014:528789. doi:10.1155/2014/528789.
[25]	Bhatt SP. Cardiac Considerations in Chronic Lung Disease. Berlin: Springer, 2020. doi:10.1007/978-3-030-43435-9.
[26]	Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J, 2023, 61(4):2300239. doi:10.1183/13993003.00239-2023.
[27]	Cazzola M, Calzetta L, Matera MG, et al. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respir Med, 2015, 109(8):1019-1025. doi:10.1016/j.rmed.2015.05.021. pmid: 26111914
[28]	Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 2006, 113(19):2335-2362. doi:10.1161/CIRCULATIONAHA.104.482570. pmid: 16702488
[29]	孙永昌. 一呼一吸总关心. 中华结核和呼吸杂志, 2019, 42(11):804-805. doi:10.3760/cma.j.issn.1001-0939.2019.11.002.
[30]	Horita N, Nagashima A, Kaneko T. Long-Acting β-Agonists (LABA) Combined With Long-Acting Muscarinic Antagonists or LABA Combined With Inhaled Corticosteroids for Patients With Stable COPD. JAMA, 2017, 318(13):1274-1275. doi:10.1001/jama.2017.11903. pmid: 28973232
[31]	Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med, 2018, 6(5):368-378. doi:10.1016/S2213-2600(18)30054-7. pmid: 29477448
[32]	Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J, 2018, 52(6):1801586. doi:10.1183/13993003.01586-2018.
[33]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组,《慢性阻塞性肺疾病合并心血管疾病诊治管理专家共识》撰写组. 慢性阻塞性肺疾病合并心血管疾病诊治管理专家共识. 中华结核和呼吸杂志, 2022, 45(12):1180-1191. doi:10.3760/cma.j.cn112147-20220505-00380.
[34]	Jing X, Li Y, Xu J. Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis. Can Respir J, 2018, 2018:7097540. doi:10.1155/2018/7097540.
[35]	Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med, 2018, 378(18):1671-1680. doi:10.1056/NEJMoa1713901.
[36]	Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med, 2020, 383(1):35-48. doi:10.1056/NEJMoa1916046.
[37]	Baker JG, Wilcox RG. β-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax, 2017, 72(3):271-276. doi:10.1136/thoraxjnl-2016-208412. pmid: 27927840
[38]	Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2005, 2005(4): CD003566. doi:10.1002/14651858.CD003566.
[39]	Etminan M, Jafari S, Carleton B, et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med, 2012, 12:48. doi:10.1186/1471-2466-12-48. pmid: 22947076
[40]	Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med, 2010, 170(10):880-887. doi:10.1001/archinternmed.2010.112. pmid: 20498416
[41]	Lipworth B, Skinner D, Devereux G, et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart, 2016, 2(23):1909-1914. doi:10.1136/heartjnl-2016-309458.
[42]	Wu J, Sin DD. Improved patient outcome with smoking cessation: when is it too late? Int J Chron Obstruct Pulmon Dis, 2011, 6:259-267. doi:10.2147/COPD.S10771.
[43]	Zhang J, Ou JX, Bai CX. Tobacco smoking in China: prevalence, disease burden, challenges and future strategies. Respirology, 2011, 16(8):1165-1172. doi:10.1111/j.1440-1843.2011.02062.x. pmid: 21910781
[44]	McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2015, 2015(2): CD003793. doi:10.1002/14651858.
[45]	Spruit MA, Burtin C, De Boever P, et al. COPD and exercise: does it make a difference? Breathe (Sheff), 2016, 12(2):38-49. doi:10.1183/20734735.003916.
[46]	Gale NS, Duckers JM, Enright S, et al. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulm Med, 2011, 11(20):1-7. doi:10.1186/1471-2466-11-20.
[47]	Huang CL, Nguyen PA, Kuo PL, et al. Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly. Comput Methods Programs Biomed, 2013, 111(2):507-511. doi:10.1016/j.cmpb.2013.05.006.
[48]	Marra F, Zhang A, Gillman E, et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis, 2020, 99(1):204-213. doi:10.1016/j.ijid.2020.07.038.

Optimizing the management of chronic obstructive pulmonary disease-reducing the risk of adverse cardiopulmonary event

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 48

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Meng Weiwei, Zeng Huihui, Chen Yan. Research progress in the application of peak inspiratory flow rate measurement in chronic airway diseases [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(5): 391-396.
[2]	Cui Yanan, Chen Yan. Programmed cell death and its research progress in chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(5): 397-406.
[3]	Luo Chenyang, He Zhiyi. Comorbidities in chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(5): 407-412.
[4]	Feng Yi, Chang Qing, Li Feng. Research progress of combined pulmonary fibrosis and emphysema [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(5): 425-431.
[5]	Liao Yixuan, Ju Yang, Wang He, Chen Jing, Du Xiaoman, Zhang Fan, Li Yanming. Analysis of current situation of respiratory medical quality control system at home and abroad [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(4): 272-276.
[6]	Zhang Xiaoxu, Xu Bei, Gu Fen. Current situation, problems and thinking of nursing management of patients with respiratory diseases [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(3): 185-188.
[7]	Lu Yu, Wang Xiaodong. Research progress of non-drug therapy for chronic obstructive pulmonary disease-related fatigue [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(3): 240-245.
[8]	. [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(1): 88-90.
[9]	Zhou Yongfang, Fu Jiangquan, Dong Wentao, Fang Donghai, Hu Xiaochun. Meta-analysis of efficacy and safety of inhaled nitric oxide in the treatment of severe and critical novel coronavirus pneumonia [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(1): 33-40.
[10]	Lu Yu, Wang Xiaodong, Jiang Qiuling, Xu Yulin. Investigation on cognition of chronic obstructive pulmonary disease related fatigue among respiratory and critical care nurses in tertiary hospitals [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(6): 490-495.
[11]	. [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(6): 526-530.
[12]	Liu Linlin, Wang Xiufen, Jiang Youli, Gui Min, Chen Jingfang. Progress in the application of pulmonary rehabilitation training for patients with post tuberculosis lung disease [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(5): 420-424.
[13]	. [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 347-352.
[14]	Zhang Xiaolin, Li Feng. Research progress of respiratory failure caused by pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 320-324.
[15]	Zhou Yinan, Zhu Huili. Research progress of chronic obstructive pulmonary disease complicated with pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2022, 3(4): 338-342.